Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2905–2928 of 84,125 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: therapy Clear all

Conditions: Psoriasis
Interventions: Brodalumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Pegfilgrastim-induced Back and Leg Pain
Interventions: Loratadine, placebo; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Brewer, Maine • Scarborough, Maine • York Village, Maine + 4 more

Conditions: Breast Cancer
Interventions: Bevacizumab, Docetaxel, Trastuzumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Hematologic Neoplasms
Interventions: Stem cell transplantation, Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, Prednisone, Methotrexate, Cyclosporine, Apheresis; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 64
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more

Conditions: Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions: anamorelin HCl, Placebo Oral Tablet; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 19
States / cities: Tucson, Arizona • Anaheim, California • Bakersfield, California + 16 more

Conditions: Cancer, Chemotherapy, Squamous Cell Carcinoma (SCC)
Interventions: Panitumumab-IRDye800; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer
Interventions: Exercise program; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 30 Years to 70 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Preterm Birth, Skin to Skin Contact, Low Birth Weight, Kangaroo Care
Interventions: Behavioral Interventions; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Interventions: Gamunex-C, 10% Injectable Solution; Drug
Lead sponsor: Grifols Biologicals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: St. Petersburg, Florida • Fort Wayne, Indiana • Westbrook, Maine + 2 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ublituximab, Placebo; Biological · Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 41
States / cities: Birmingham, Alabama • Cullman, Alabama • Orange, California + 34 more

Conditions: Nutritional Physiological Phenomena, Obesity
Interventions: Sugar Sweetened Solid Treatment, Sugar Sweetened Beverage Treatment; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: GBAT+Individual, GBAT+Engagement Booster, GBAT+Both
Interventions: GBAT+I, GBAT+E - Phase I, Watchful Waiting and Groups - Phase 2, GBAT+IE; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 40 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions: bendamustine, rituximab, vincristine, prednisone, cyclophosphamide, doxorubicin; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 79
States / cities: Tucson, Arizona • Little Rock, Arkansas • Corona, California + 70 more

Conditions: Heart Defects, Congenital
Interventions: Music Therapy; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Days to 30 Days
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Back Pain
Interventions: Treatment with BTL-043, BTL-899; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Scottsdale, Arizona • Fort Myers, Florida • Columbus, Ohio + 1 more

Conditions: Breast Cancer, Ovarian Neoplasm, Pain
Interventions: Omega-3 fatty acid, Placebo, Paclitaxel; Dietary Supplement · Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Albuquerque, New Mexico

Conditions: Lymphoma
Interventions: rituximab, bortezomib, pegylated liposomal doxorubicin hydrochloride, gene expression analysis, polymerase chain reaction, polymorphism analysis, proteomic profiling, flow cytometry, laboratory biomarker analysis; Biological · Drug · Genetic + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: HIV Infections, Lipodystrophy
Interventions: Leptin, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 14 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Child Disruptive Behavior Disorders, Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Triple P Online System, Placebo Comparator; Other · Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 3 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Eugene, Oregon • Seattle, Washington

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: Carvedilol; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Insomnia
Interventions: Assisted Relaxation Therapy, Modified Assisted Relaxation Therapy; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain, Inflammation, Cataract
Interventions: Bromfenac Ophthalmic Solution, Placebo; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Irvine, California

Conditions: Twin Twin Transfusion Syndrome
Interventions: Selective Laser Photocoagulation of Communicating Vessels; Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain

Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2

A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures

Exercise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Breast Conservation Therapy for Women With Early Stage Breast Cancer

Promoting Kangaroo Care for Preterm or Low Birthweight Infants in Rural India

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

The DEB Pilot Study

Transdiagnostic Group Therapy (GBAT) for Autistic Adults With Personalized Therapeutics

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

The Use of Music for Neonates Post-Cardiac Surgery

Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Therapeutic Approaches to HAART-Induced Lipodystrophy

Evaluating an Online Parenting Support System Disseminated by Pediatric Practices

Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells

Behavioral Relaxation Approaches for Insomnia in Lung Cancer Patients

Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

Selective Laser Photocoagulation of Communicating Vessels in Twin-Twin Transfusion Syndrome